Literature DB >> 16236417

The effect of antidepressant treatment on N-acetyl aspartate levels of medial frontal cortex in drug-free depressed patients.

Ali Saffet Gonul1, Omer Kitis, Erol Ozan, Fisun Akdeniz, Cagdas Eker, Ozlem Donat Eker, Simavi Vahip.   

Abstract

The medial frontal cortex has been shown to modulate emotional behavior and stress responses, suggesting that the dysfunction of this region may be involved in the pathogenesis of depressive symptoms. The present study was performed to determine whether there was any effect of antidepressant treatment on the metabolite levels in the left medial frontal cortex as measured by proton magnetic resonance spectroscopy in depressed patients. Twenty patients diagnosed as having major depressive disorder according to DSM-IV and 18 healthy volunteer subjects were included in the study. Twelve of patients had their first episode and were drug-naïve. Other depressed patients were drug-free for at least 4 weeks. The severity of depression was assessed by HAM-D and Clinical Global Impression Scale-Severity (CGI-S). Single voxel, 8 cm(3), 1H MR spectra of left medial frontal cortex was acquired both before and following antidepressant treatment. The concentrations and ratios of N-acetyl aspartate (NAA), Creatine+Phosphocreatine (Cr+PCr) and Choline (Cho) were measured. Pretreatment NAA/Cr values of patients were lower than those of healthy controls, but this difference did not reach to statistically significant levels (t=1.83, df=36, p=0.07). However, antidepressant treatment had significant effect on NAA/Cr ratios (groupxtreatment interaction: F=9.93 df=1,36, p=0.03). After the treatment, NAA/Cr values of patients increased significantly compared to pretreatment values (t=3.32, df=19, p=0.004). No significant difference was observed between the post-treatment NAA/Cr values of patients and those of controls (t=1.64, df=36, p=0.19). Correlation analysis detected negative correlation between pretreatment CGI-S scores and NAA/Cr ratios (r=-0.51, p=0.02). This preliminary result suggests that there might be a possible defect in the neuronal integrity in the left medial frontal cortex (mainly left anterior cingulate cortex) of depressed patients. Antidepressant treatment with its neurotrophic effects might play a positive role in restoring the neuronal integrity. Further studies are needed to support these initial findings.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16236417     DOI: 10.1016/j.pnpbp.2005.08.017

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  21 in total

Review 1.  Magnetic resonance spectroscopy in the evaluation of treatment efficacy in unipolar major depressive disorder: a review of the literature.

Authors:  Eduardo Caverzasi; Anna Pichiecchio; Guy Umberto Poloni; Alessandro Calligaro; Moreno Pasin; Fulvia Palesi; Gloria Castellazzi; Massimo Pasquini; Massimo Biondi; Francesco Barale; Stefano Bastianello
Journal:  Funct Neurol       Date:  2012 Jan-Mar

2.  Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease.

Authors:  A Sturrock; C Laule; J Decolongon; R Dar Santos; A J Coleman; S Creighton; N Bechtel; R Reilmann; M R Hayden; S J Tabrizi; A L Mackay; B R Leavitt
Journal:  Neurology       Date:  2010-11-09       Impact factor: 9.910

3.  A comparison of affected and unaffected relatives of patients with bipolar disorder using proton magnetic resonance spectroscopy.

Authors:  Tomas Hajek; Denise Bernier; Claire Slaney; Lukas Propper; Matthias Schmidt; Normand Carrey; Glenda MacQueen; Anne Duffy; Martin Alda
Journal:  J Psychiatry Neurosci       Date:  2008-11       Impact factor: 6.186

4.  Neurochemical alterations in adolescent bipolar depression: a proton magnetic resonance spectroscopy pilot study of the prefrontal cortex.

Authors:  Nick C Patel; Kim M Cecil; Stephen M Strakowski; Caleb M Adler; Melissa P DelBello
Journal:  J Child Adolesc Psychopharmacol       Date:  2008-12       Impact factor: 2.576

5.  Effects of fish oil supplementation on prefrontal metabolite concentrations in adolescents with major depressive disorder: a preliminary 1H MRS study.

Authors:  Robert K McNamara; Ronald Jandacek; Therese Rider; Patrick Tso; Wen-Jang Chu; Wade A Weber; Jeffrey A Welge; Jeffrey R Strawn; Caleb M Adler; Melissa P DelBello
Journal:  Nutr Neurosci       Date:  2016-03-02       Impact factor: 4.994

6.  Experience of social discrimination correlates with neurometabolism: a pilot study in heroin addicts.

Authors:  Ulrich Frischknecht; Derik Hermann; Milena Heinrich; Mareen Hoerst; Wolfgang Weber-Fahr; Sabine Vollstädt-Klein; Falk Kiefer; Karl Mann; Gabriele Ende
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-05-09       Impact factor: 5.270

7.  Early increase in marker of neuronal integrity with antidepressant treatment of major depression: 1H-magnetic resonance spectroscopy of N-acetyl-aspartate.

Authors:  Matthew J Taylor; Beata R Godlewska; Ray Norbury; Sudhakar Selvaraj; Jamie Near; Philip J Cowen
Journal:  Int J Neuropsychopharmacol       Date:  2012-03-26       Impact factor: 5.176

8.  Review: magnetic resonance spectroscopy studies of pediatric major depressive disorder.

Authors:  Douglas G Kondo; Tracy L Hellem; Young-Hoon Sung; Namkug Kim; Eun-Kee Jeong; Kristen K Delmastro; Xianfeng Shi; Perry F Renshaw
Journal:  Depress Res Treat       Date:  2010-10-04

9.  A MRS study of metabolic alterations in the frontal white matter of major depressive disorder patients with the treatment of SSRIs.

Authors:  Yifan Zhang; Yu Han; Yongzhi Wang; Yinfeng Zhang; Li Li; Erhu Jin; Ligang Deng; Brandi Watts; Teresa Golden; Ning Wu
Journal:  BMC Psychiatry       Date:  2015-05-02       Impact factor: 3.630

10.  Neurometabolic characteristics in the anterior cingulate gyrus of Alzheimer's disease patients with depression: a (1)H magnetic resonance spectroscopy study.

Authors:  Zhongwei Guo; Jiangtao Zhang; Xiaozheng Liu; Hongtao Hou; Yulin Cao; Fuquan Wei; Japeng Li; Xingli Chen; Yuedi Shen; Wei Chen
Journal:  BMC Psychiatry       Date:  2015-12-02       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.